In a nutshell This trial was carried out to examine the effectiveness and safety profile of pembrolizumab (Keytruda) and nivolumab (Opdivo) for the treatment of classical Hodgkin lymphoma (cHL) that has relapsed and is refractory (resistant to drug treatment). The authors found that...Read More
Current treatment status-Undergoing active treatment-No response Posts on Medivizor
Does a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?
In a nutshell This study aimed to assess the effectiveness and safety of two doses of cabazitaxel (Jevtana) (20 or 25 mg/m2) in the treatment of castration-resistant prostate cancer (CRPC) in the real-world practice. The study found that a lower dose of cabazitaxel benefited patients at high risk of having side...Read More
Looking for patients with metastatic non-small cell lung cancer to trial a biological treatment combination
In a nutshell This trial is being carried out to assess the effectiveness of atezolizumab (Tecentriq) in combination with cabozantinib (Cabometyx) versus docetaxel (Taxotere) in patients with metastatic non-small cell lung cancer (NSCLC) which has previously been treated with immunotherapy and platinum-based chemotherapy....Read More
In a nutshell This study looked at MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, etoposide) to treat patients over 70 with non-Hodgkin’s lymphoma (NHL) which had returned after previous treatments. It found that MTX-HOPE was an effective and safe treatment for these patients. Some background NHL is a group of cancers of the...Read More
In a nutshell This study aimed to compare two salvage regimes for patients with relapsed/refractory acute myeloid leukemia. This study concluded that both regimens have similar effectiveness in terms of overall response but one shows a significant reduction in side effects in these patients. Some background...Read More
In a nutshell This study looked at abemaciclib (Verzenio), trastuzumab (Herceptin), and fulvestrant (Faslodex) for the treatment of advanced hormone-receptor-positive (HR+) and HER2 positive (HER2+) breast cancer. It found that this treatment led to better outcomes than standard-of-care chemotherapy for these patients. Some background Worldwide,...Read More
The benefits of repeated cytoreductive surgery and hyperthermic peritoneal chemotherapy in advanced colorectal cancer
In a nutshell This study investigated the benefits of repeated cytoreductive surgery (CRS) and hyperthermic peritoneal chemotherapy (HIPEC) in patients with advanced colorectal cancer. Researchers suggested that repeated treatment improves the survival of patients with advanced colorectal cancer, without an increase in side effects. Some background...Read More
Switching from imatinib to dasatinib in the case of sub-optimal response in chronic myeloid leukemia
In a nutshell This study aimed to investigate the outcome of early switching from imatinib to dasatinib of patients with chronic-phase chronic myeloid leukemia with weak responses to imatinib treatment. The study concluded that this switch may offer clinical benefit in certain patients. Some background Imatinib...Read More
How effective and safe is high-dose chemotherapy and stem cell transplant for children with lymphoma?
In a nutshell This study examined the effectiveness and safety of high-dose chemotherapy and stem cell transplants for children with lymphoma. The study showed that the combination treatment was very effective but that the dose may need to be adjusted for some patients. Some background Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) have very...Read More
In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) in elderly patients with relapsed or unresponsive Hodgkin lymphoma (HL). This study found that this treatment was effective, although frail patients may be at higher risk for side effects. Some background Most patients with HL respond to front-line...Read More
In a nutshell This article reviews treatment options for patients with classical Hodgkin's lymphoma (cHL) that came back (relapsed) after chemotherapy. This study found that targeted therapies are becoming more prevalent and that patient outcomes have improved. Some background cHL is a cancer of white blood cells called lymphocytes....Read More
Have outcomes improved for patients with Hodgkin’s lymphoma who relapse after a stem cell transplant?
In a nutshell This study evaluated the long-term outcomes of patients with classical Hodgkin’s lymphoma (cHL) that came back after an autologous stem cell transplant (autoSCT). This study found that advancements in treatment have helped improve survival outcomes for patients. Some background Chemotherapy is usually the first-line...Read More